热门资讯> 正文
Immix Bizerma为美国AL淀粉样变性试验中的首例患者接种疫苗
2024-07-09 02:04
- Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201.
- The company added that the timing of the milestone was in-line with its mid-2024 guidance.
- It also added that the data from its ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate.
- Shares of IMMX dropped 7.20% to $2.19 during market hours.
- Press release.
More on Immix Biopharma, Inc.
- Seeking Alpha’s Quant Rating on Immix Biopharma, Inc.
- Historical earnings data for Immix Biopharma, Inc.
- Financial information for Immix Biopharma, Inc.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
